Core Framework & Diagram The Future of CAR-T
July 23, 20261 Min Read The Future of Cancer Vaccines
July 24, 2026CAR-T changed the treatment rules for blood cancers — where will it go in the next decade?
—— From first generation to next generation: CAR-T technology's evolution roadmap and its collaborative prospects with NK cell therapy.
I. Universal CAR-T: making cell therapy a 'stockable drug'
Current CAR-T's biggest practical obstacle isn't technical — it's the production model: highly individualized, needing each patient's T cells taken out, manufactured in a factory, then sent back to that patient. This process takes four to eight weeks, costs $300,000–500,000, and some patients (like elderly patients with poor T cell quality or post-chemotherapy patients) can't even have their T cells meet manufacturing requirements. Universal CAR-T (Allogeneic/Universal CAR-T, also called ALLO-CAR-T) tries to solve this problem: using healthy donors' (or iPSC-derived) T cells to manufacture a batch of standardized CAR-T products, stored until needed, taken directly when required — like ordinary medicines.
Core technical challenges: GvHD (graft-versus-host disease) — allogeneic T cells carry the donor's own TCR, which will recognize and attack recipient's normal tissues. Solution: CRISPR knockout of donor T cells' TCR gene (TCR-alpha chain), eliminating GvHD's root cause; being rejected by recipient's immune system — solution: CRISPR knockout of donor T cells' HLA-A/B genes, reducing the possibility of being recognized and cleared by recipient NK and T cells. In 2023, Allogene Therapeutics and other companies' universal CAR-T products have had Phase 1 clinical trial data — showing remission in some patients without serious GvHD. CAR-NK is naturally a better 'universal type' candidate — NK cells don't express complete TCR (therefore won't cause GvHD), can use allogeneic products, and the MD Anderson team's CAR-NK clinical trial (2020, NEJM) already proved its safety.
2. Solid tumors: CAR-T's most important battlefield in the next decade
Blood tumors' success is exciting, but blood tumors only account for approximately ten percent of all cancers. The other ninety percent are solid tumors — lung cancer, colorectal cancer, breast cancer, pancreatic cancer... In these cancers, CAR-T is currently almost ineffective. Solid tumor's three major barriers and solutions being explored: Barrier 1: CAF physical barriers prevent CAR-T from entering tumor cores — solution: introduce hyaluronidase (HYAL) secretion genes in CAR-T, letting CAR-T secrete matrix-degrading enzymes when reaching tumors, 'opening its own path'; combine with oncolytic viruses (OV): OV first breaks down tumor physical structure through infection, opening CAR-T's entry channel, then CAR-T conducts precision cleanup.
Barrier 2: TME's low-glucose, high-lactate, adenosine and other metabolic suppression — Solution A: change key metabolic genes in CAR-T, like expressing mutant PGC-1α (enhancing mitochondrial biogenesis, letting CAR-T maintain activity using OXPHOS in low-glucose environments); Solution B: introduce adenosine deaminase (ADA) gene, letting CAR-T degrade surrounding adenosine in high-adenosine TME, protecting itself from being 'anesthetized.' Barrier 3: antigen heterogeneity — not all tumor cells express targeting antigen; single-target CAR-T creates selection pressure after which antigen-negative tumor cells expand (antigen escape) — solutions: tandem CAR (one CAR carrying two scFvs, recognizing two antigens); bivalent CAR (two CARs in the same T cell); SynNotch-assisted logic gates (AND logic recognition, requiring both antigens simultaneously to activate, reducing single-antigen escape selection pressure).
3. Armored CAR-T: installing self-sufficient 'arsenals' for CAR-T
'Armored CAR-T' (4th Generation CAR-T) builds on standard CAR-T to introduce additional functional modules — most commonly letting CAR-T simultaneously secrete molecules that support itself or transform the surrounding environment when recognizing tumors: self-secreting IL-15 — IL-15 is one of NK cells' and T cells' most important survival factors. CAR-T with introduced IL-15 self-secretion circuits can self-sufficiently maintain proliferation signals in the body without depending on exogenous IL-2, significantly improving persistence. Simultaneously, IL-15 secreted locally can also activate NK cells and T cells inside tumors, producing 'bystander activation' effects, expanding anti-tumor immune coverage.
Self-secreting IL-12 — IL-12 can activate dendritic cells and macrophages, promoting inflammatory remodeling in tumor microenvironments (M2→M1), warming cold tumors. 'TRUCK'-type CAR-T that secretes IL-12 locally inside tumors shows superior anti-tumor effects to standard CAR-T in animal models, especially significant for solid tumors. Secreting PD-L1-blocking antibodies — letting CAR-T continuously secrete trace amounts of PD-L1 monoclonal antibodies locally in tumors, maintaining local PD-1/PD-L1 blockade inside the tumor microenvironment, without needing systemic intravenous injection of large-dose checkpoint inhibitors — smaller side effects, higher local concentration.
4. CAR-T and NK cell therapy collaboration: two-army encirclement
From the complementary targeting mechanism perspective: CAR-T depends on MHC molecule presentation of target antigens (if tumors downregulate MHC, CAR-T can't see target cells); NK cells recognize MHC-low-expressing tumor cells through 'missing self' (what CAR-T can't see, NK cells can find); combining both creates 'dual surveillance' — regardless of whether tumors retain MHC (CAR-T pursues and kills) or lose MHC (NK cells pursue and kills), the tumor has nowhere to hide. From the microenvironment transformation perspective: CAR-T after activation secretes IFN-γ, upregulating tumor cells' MHC-I expression; NK cells' early arrival and innate immune activation (secreting IFN-γ, activating dendritic cells), providing better microenvironment for subsequent CAR-T's activation and survival in tumors. This 'two-army encirclement' collaborative strategy is currently mainly at clinical preclinical research stage, but several teams have begun designing sequential treatment regimens of 'CAR-NK leading, CAR-T following.'
5. In vivo CAR-T: moving 'manufacturing' inside the patient
Current CAR-T products are all 'ex vivo manufactured.' In Vivo CAR-T is a completely different approach: directly injecting viral vectors or lipid nanoparticles (LNP) carrying CAR genes into patients intravenously, completing T cell modification inside the body — moving the manufacturing location from the factory to the patient's own body. University of Pennsylvania's Michael Mitchell team published a proof-of-concept study in Science in 2022: using T cell-targeting LNP (modified with CD3 antibody fragments on the particle surface, making it target T cells) to encapsulate CAR's mRNA, after injection in mice, LNP targeted T cells, mRNA entered T cells, T cells expressed CAR and showed anti-tumor effects — completed entirely in the body, without ex vivo cell engineering. If in vivo CAR-T can be achieved in humans, its disruptive nature is profound: one intravenous injection replacing weeks of individualized cell manufacturing, cost potentially dropping from hundreds of thousands of dollars to possibly thousands of dollars.
|
In vivo CAR-T is the critical step transforming CAR-T therapy from 'luxurious individualized customization' to 'mass-popularizable standard treatment.' If it succeeds in humans, it will be the greatest accessibility revolution in cell therapy history. |
6. CAR-T technology's 2030 vision
Based on current technology progress: blood tumor domain — universal CAR-T/CAR-NK products become standard treatment options, cost greatly decreasing (from $300,000–500,000 to $50,000–100,000), waiting time shrinking from weeks to days or less; solid tumor domain — first CAR-T/CAR-NK products for specific solid tumor targets receive approval, combination regimens with oncolytic viruses or TME remodeling become standard paradigms; technology — Armored CAR-T (IL-15 self-secretion, SynNotch logic gates, metabolic enhancement) enters late-stage clinical trials; in vivo CAR-T enters human Phase 1 trials; ecosystem — CAR-T and NK cell therapy collaborative regimens become optimized cell therapy standards in specific cancer types; NK cell therapy gains broader clinical recognition as an alternative for patients unsuitable for CAR-T.
Frequently Asked Questions